Application Note: Increase Efficiency in B Cell Workflows for Clinical and Biotherapeutic Research and Antibody Development
Last updated: September 25, 2023
Overview
The development of immunotherapeutics has seen a marked increase in recent years with the most robust method for monoclonal antibody (mAb) discovery being the use of immune B cells in hybridoma studies. The significance of immune based therapies lies in the manipulation of the host’s own immune system to fight off disease. Taking immunized animals as a source, extracted plasma cells, such as B cells, can be fused with myeloma cells to generate immortalized hybridomas that can produce antibodies indefinitely.
These antibodies will be targeted to the infective agent the animal is treated with. The main drawback with this method of antibody production is the generation of hybridomas, which are time consuming, costly, require labor intensive processes to develop and are inefficient; around 1 in 5000 B cells survive fusion into hybridomas.
This application note highlights the advantages of employing the CellCelector Flex in B cell workflows for increased efficiency and shorter timescales in clinical and biotherapeutic research and antibody development.
- Document type: Application Note
- Page count: 8
- Read time: 15 minutes
Key Takeaways
- The opportunity to screen, characterize and pick B cells within hours, rather than days using a single system with the CellCelector Flex platform.
- High efficiency, accuracy and automated protocols remove the need for intensive, inconsistent manual handling of biological material
- Ease of use, one system is required to identify, isolate and characterize B cells
